Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPJT-026
- Development stage
- Phase 1
- Lead developer
- Lepu Jiantang Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
LPJT-026 is a long-acting basal insulin analog developed by Lepu Jiantang Pharmaceutical (a subsidiary of Lepu Medical) for the treatment of type 2 diabetes mellitus. It is designed for once-weekly subcutaneous administration, aiming to provide a more convenient dosing regimen than traditional once-daily basal insulins like insulin glargine. By binding to and activating the insulin receptor, LPJT-026 promotes glucose disposal in peripheral tissues and suppresses hepatic glucose production. The drug is currently in Phase I clinical development, with studies utilizing glucose clamp methodology to evaluate its safety, pharmacokinetics, and pharmacodynamics in comparison to insulin glargine and placebo.
Beyond the preview
Go deeper on LPJT-026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPJT-026.